Celldex Therapeutics (CLDX) Cash from Investing Activities (2010 - 2026)

Celldex Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $72.1 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 67.91% year-over-year to $72.1 million in Q1 2026; TTM through Mar 2026 was $238.2 million, a 250.19% increase from a year earlier, with the FY2025 full-year figure at $209.1 million, up 172.06% from the prior year.
• Cash from Investing Activities improved to $72.1 million in Q1 2026 per CLDX's latest filing, from $55.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $72.1 million in Q1 2026 and bottomed at -$315.2 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is $25.3 million (2022), against an average of -$1.5 million.
• Across the five-year window, Cash from Investing Activities jumped 406.45% in 2023 and tumbled 4114.0% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $31.2 million in 2022, then tumbled by 648.36% to -$171.2 million in 2023, then jumped by 114.05% to $24.0 million in 2024, then jumped by 130.49% to $55.4 million in 2025, then soared by 30.12% to $72.1 million in 2026.
• Per Business Quant, the three latest CLDX Cash from Investing Activities figures stand at $72.1 million (Q1 2026), $55.4 million (Q4 2025), and $60.8 million (Q3 2025).